Thursday February 20, 2020

Start-up ATXA Therapeutics lands €2.5m in EU funding to develop orphan drug

27th May, 2018
Therese Kinsella, founder, ATXA Therapeutics

Company: ATXA Therapeutics

Done Deal:€2.5m funding

The clincher:“There is urgent unmet clinical need with regard to PAH, because the current drugs don’t work. They are failing patients” – Therese Kinsella, founder

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Related Stories

What’s coming up today and what you might have missed

Hannah O’Brien | 2 months ago

What’s coming up today and what you might have missed.

Hannah O’Brien | 2 months ago